InsightfulValue
← Home

Gilead Sciences
Gilead Sciences

Pharma / Pharma


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

Gilead Sciences

πŸ“Š Get full analytics about Gilead Sciences

Sign up for free or log in

⚑ Instantly access "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free!

Price
Live  
Infographic
Infographics
Overview
Gilead Sciences is an American biopharmaceutical company that focuses on the development and commercialization of innovative medicines for the treatment of life-threatening diseases. The company was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences is known for its groundbreaking work in the field of HIV/AIDS. In 1996, the company launched its first HIV medication, Viread, which was the first of its kind to be approved by the US Food and Drug Administration (FDA). Since then, Gilead has developed and commercialized other HIV medications, including Truvada, Atripla, and Biktarvy.
In addition to its work in HIV/AIDS, Gilead Sciences has expanded into other areas of medicine, including hepatitis C, liver diseases, and oncology. In 2017, the company acquired Kite Pharma, a leader in the development of personalized cancer therapies, further diversifying its portfolio.
Gilead Sciences has a global presence, with operations in North America, Europe, Asia, and Latin America. The company currently employs over 12,000 people worldwide and has a market capitalization of over $90 billion.
In recent years, Gilead Sciences has faced criticism for the high prices of its medications, particularly for its HIV and hepatitis C treatments. The company has implemented various initiatives to increase access to its medicines for patients in need, including partnerships with generic drug manufacturers and patient assistance programs.
How to explain to a 10 year old kid about the company?
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

πŸ“– Get insights from "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" now!

R2lsZWFkIF NjaWVuY2Vz IGlzIGEgY2 9tcGFueSB0 aGF0IGZvY3 VzZXMgb24g bWFraW5nIG 1lZGljaW5l cywgZXNwZW NpYWxseSBm b3Igc2VyaW 91cyBkaXNl YXNlcyBsaW tlIEhJViwg bGl2ZXIgcH JvYmxlbXMs IGFuZCBzb2 1lIHR5cGVz IG9mIGNhbm Nlci4gSW1h Z2luZSBHaW xlYWQgYXMg YSBzdXBlcm hlcm8gdGhh dCBjcmVhdG VzIHNwZWNp YWwgcG90aW 9ucyB0byBo ZWxwIHBlb3 BsZSBmZWVs IGJldHRlci BhbmQgbGl2 ZSBoZWFsdG hpZXIgbGl2 ZXMuPGJyPl RoZSB3YXkg R2lsZWFkIG 1ha2VzIG1v bmV5IGlzIG J5IGNyZWF0 aW5nIHRoZX NlIG1lZGlj aW5lcyBhbm QgdGhlbiBz ZWxsaW5nIH RoZW0gdG8g aG9zcGl0YW xzIGFuZCBw aGFybWFjaW VzLiBEb2N0 b3JzIHVzZS B0aGVzZSBt ZWRpY2luZX MgdG8gaGVs cCBwYXRpZW 50cyBnZXQg YmV0dGVyLC BhbmQgdGhl IGhvc3BpdG FscyBwYXkg R2lsZWFkIG ZvciB0aGUg ZHJ1Z3MuIF NvbWV0aW1l cywgdGhleS BhbHNvIHdv cmsgd2l0aC BiaWcgcmVz ZWFyY2ggZ3 JvdXBzIHRv IGRpc2Nvdm VyIG5ldyBt ZWRpY2luZX MsIGFuZCB0 aGlzIGNhbi BicmluZyBp biBldmVuIG 1vcmUgbW9u ZXkuPGJyPk dpbGVhZCBp cyBzdWNjZX NzZnVsIGZv ciBhIGZldy ByZWFzb25z LiBGaXJzdC wgdGhleSBp bnZlc3QgYS Bsb3Qgb2Yg dGltZSBhbm QgbW9uZXkg aW50byByZX NlYXJjaCB0 byBmaW5kIG 5ldyB0cmVh dG1lbnRzLi BUaGlzIG1l YW5zIHRoZX nigJlyZSBh bHdheXMgdH J5aW5nIHRv IGNyZWF0ZS BiZXR0ZXIg YW5kIG1vcm UgZWZmZWN0 aXZlIG1lZG ljaW5lcy4g U2Vjb25kLC B0aGV5IGhh dmUgc3Ryb2 5nIHBhdGVu dHMsIHdoaW NoIGFyZSBs aWtlIHByb3 RlY3RpdmUg c2hpZWxkcy B0aGF0IGtl ZXAgb3RoZX IgY29tcGFu aWVzIGZyb2 0gY29weWlu ZyB0aGVpci BkcnVncyBm b3IgYSBjZX J0YWluIG51 bWJlciBvZi B5ZWFycy4g VGhpcyBoZW xwcyB0aGVt IHNlbGwgdG hlaXIgbWVk aWNpbmVzIH dpdGhvdXQg bXVjaCBjb2 1wZXRpdGlv bi4gTGFzdG x5LCBhcyBt b3JlIHBlb3 BsZSBhcm91 bmQgdGhlIH dvcmxkIG5l ZWQgaGVhbH RoY2FyZSBh bmQgYmV0dG VyIHRyZWF0 bWVudHMsIE dpbGVhZCBp cyB3ZWxsLX Bvc2l0aW9u ZWQgdG8gaG VscCB0aGVt LCB3aGljaC BtZWFucyB0 aGV5IHdpbG wgbGlrZWx5 IGNvbnRpbn VlIHRvIGJl IHN1Y2Nlc3 NmdWwgaW4g dGhlIGZ1dH VyZS48YnI+ SW4gc3VtbW FyeSwgR2ls ZWFkIFNjaW VuY2VzIGlz IGdvb2QgYX QgbWFraW5n IG1lZGljaW 5lcyB0aGF0 IGhlbHAgZm lnaHQgYmln IGlsbG5lc3 NlcywgdGhl eSBrbm93IG hvdyB0byBt YWtlIG1vbm V5IGJ5IHNl bGxpbmcgdG hvc2UgbWVk aWNpbmVzLC BhbmQgdGhl eSBoYXZlIH RoZSBza2ls bHMgYW5kIH BsYW5zIHRv IHJlbWFpbi BhIHN0cm9u ZyBwbGF5ZX IgaW4gdGhl IGhlYWx0aG NhcmUgaW5k dXN0cnkgZm 9yIHllYXJz IHRvIGNvbW UuPGJyPg==
What is special about the company?
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

πŸ“š Your free copy of "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" is waiting

R2lsZWFkIF NjaWVuY2Vz IGlzIGEgYm lvcGhhcm1h Y2V1dGljYW wgY29tcGFu eSB0aGF0IG lzIHBhcnRp Y3VsYXJseS Bub3RhYmxl IGZvciBzZX ZlcmFsIHJl YXNvbnMuIE ZpcnN0LCBp dCBoYXMgYS BzdHJvbmcg Zm9jdXMgb2 4gYW50aXZp cmFsIGRydW dzLCBlc3Bl Y2lhbGx5IH Rob3NlIHVz ZWQgdG8gdH JlYXQgaW5m ZWN0aW9ucy BsaWtlIEhJ Vi9BSURTLC BoZXBhdGl0 aXMgQiwgaG VwYXRpdGlz IEMsIGFuZC BpbmZsdWVu emEuIEdpbG VhZCBpcyB3 aWRlbHkgcm Vjb2duaXpl ZCBmb3IgaX RzIGRldmVs b3BtZW50IG 9mIHJldm9s dXRpb25hcn kgSElWIG1l ZGljYXRpb2 5zIGFuZCB0 cmVhdG1lbn RzIGZvciBo ZXBhdGl0aX MgQyB0aGF0 IGhhdmUgc2 lnbmlmaWNh bnRseSBpbX Byb3ZlZCBw YXRpZW50IG 91dGNvbWVz Ljxicj5Bbm 90aGVyIGFz cGVjdCB0aG F0IHNldHMg R2lsZWFkIG FwYXJ0IGlz IGl0cyBjb2 1taXRtZW50 IHRvIHJlc2 VhcmNoIGFu ZCBkZXZlbG 9wbWVudC4g VGhlIGNvbX BhbnkgaW52 ZXN0cyBoZW F2aWx5IGlu IHNjaWVudG lmaWMgaW5u b3ZhdGlvbi wgd2hpY2gg aGFzIGxlZC B0byB0aGUg ZGlzY292ZX J5IG9mIG5l dyB0aGVyYX BpZXMgYW5k IGVuaGFuY2 VtZW50IG9m IGV4aXN0aW 5nIHRyZWF0 bWVudHMuIF RoaXMgZm9j dXMgb24gUi ZhbXA7RCBo YXMgcG9zaX Rpb25lZCBH aWxlYWQgYX MgYSBsZWFk ZXIgaW4gdG hlIGJpb3Bo YXJtYWNldX RpY2FsIHNl Y3Rvci48Yn I+QWRkaXRp b25hbGx5LC BHaWxlYWQg aGFzIG1hZG UgaGVhZGxp bmVzIGZvci BpdHMgcm9s ZSBpbiBhZG RyZXNzaW5n IHB1YmxpYy BoZWFsdGgg Y3Jpc2VzLi BGb3IgZXhh bXBsZSwgZH VyaW5nIHRo ZSBDT1ZJRC 0xOSBwYW5k ZW1pYywgR2 lsZWFkIGRl dmVsb3BlZC ByZW1kZXNp dmlyLCBhbi BhbnRpdmly YWwgZHJ1Zy B0aGF0IGJl Y2FtZSBvbm Ugb2YgdGhl IGZpcnN0IH RyZWF0bWVu dHMgYXV0aG 9yaXplZCBm b3IgdXNlIG FnYWluc3Qg Q09WSUQtMT kuPGJyPlRo ZSBjb21wYW 554oCZcyBi dXNpbmVzcy Btb2RlbCBh bHNvIGluY2 x1ZGVzIGEg Y29tbWl0bW VudCB0byBh Y2Nlc3MgYW 5kIGFmZm9y ZGFiaWxpdH ksIHN0cml2 aW5nIHRvIH Byb3ZpZGUg aXRzIG1lZG ljYXRpb25z IHRvIHBhdG llbnRzIGFy b3VuZCB0aG Ugd29ybGQs IHBhcnRpY3 VsYXJseSBp biBsb3ctIG FuZCBtaWRk bGUtaW5jb2 1lIGNvdW50 cmllcy48Yn I+T3ZlcmFs bCwgR2lsZW FkIFNjaWVu Y2VzIGlzIG Rpc3Rpbmd1 aXNoZWQgYn kgaXRzIGlu bm92YXRpdm UgZHJ1ZyBk ZXZlbG9wbW VudCwgZm9j dXMgb24gY3 JpdGljYWwg dmlyYWwgaW 5mZWN0aW9u cywgYW5kIG l0cyByb2xl IGluIGFkZH Jlc3Npbmcg Z2xvYmFsIG hlYWx0aCBj aGFsbGVuZ2 VzLjxicj4=
What the company's business model?
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

πŸ†“ Discover "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free eBook!

VGhlIEdpbG VhZCBTY2ll bmNlcyBjb2 1wYW55J3Mg YnVzaW5lc3 MgbW9kZWwg aXMgZm9jdX NlZCBvbiBk ZXZlbG9waW 5nIGFuZCBj b21tZXJjaW FsaXppbmcg aW5ub3ZhdG l2ZSBtZWRp Y2luZXMgaW 4gYXJlYXMg b2YgaGlnaC B1bm1ldCBt ZWRpY2FsIG 5lZWQuIFRo aXMgaW5jbH VkZXMgY29u ZHVjdGluZy ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQgZm9yIH RyZWF0bWVu dHMgb2Ygdm lyYWwsIGxp dmVyLCBpbm ZsYW1tYXRp b24sIGFuZC BvbmNvbG9n eSBkaXNlYX Nlcy4gVGhl IGNvbXBhbn kgYWxzbyBz dHJpdmVzIH RvIGltcHJv dmUgYWNjZX NzIHRvIGl0 cyB0aGVyYX BpZXMgZm9y IHBhdGllbn RzIGFyb3Vu ZCB0aGUgd2 9ybGQsIHdo aWxlIG1haW 50YWluaW5n IGEgc3Ryb2 5nIGZpbmFu Y2lhbCBwZX Jmb3JtYW5j ZSBhbmQgZG VsaXZlcmlu ZyB2YWx1ZS B0byBpdHMg c2hhcmVob2 xkZXJzLiBH aWxlYWQncy BhcHByb2Fj aCBpbmNsdW RlcyBjb2xs YWJvcmF0aW 9ucyBhbmQg cGFydG5lcn NoaXBzIHdp dGggb3RoZX IgY29tcGFu aWVzLCBnb3 Zlcm5tZW50 IGFnZW5jaW VzLCBhbmQg bm9uLXByb2 ZpdCBvcmdh bml6YXRpb2 5zLCBhcyB3 ZWxsIGFzIG ludmVzdG1l bnRzIGluIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCB0byBkaX Njb3ZlciBh bmQgZGV2ZW xvcCBuZXcg dHJlYXRtZW 50cyBhbmQg ZXhwYW5kIH RoZSB1c2Ug b2YgaXRzIG V4aXN0aW5n IHByb2R1Y3 RzLg==
Is AI a threat?
AI does pose potential threats to Gilead Sciences, primarily through substitution, disintermediation, and margin pressure, but the extent of these threats is influenced by various factors specific to the pharmaceutical industry.
1. Substitution: AI technologies are advancing rapidly, particularly in drug discovery and development. Machine learning algorithms can analyze vast datasets to identify new drug candidates, which could lead to the development of competing therapies that may replace existing Gilead products. Additionally, AI-driven personalized medicine approaches could tailor treatments more effectively than Gilead’s current offerings, potentially eroding market share if Gilead does not adapt.
2. Disintermediation: AI could change the traditional pharmaceutical supply chain and patient care models. For instance, AI-enabled platforms could facilitate direct connections between drug developers and patients, bypassing traditional distribution channels. This shift could challenge Gilead’s ability to reach customers effectively, reducing the role of established intermediaries like pharmacies and distributors.
3. Margin Pressure: The implementation of AI in healthcare often aims to increase efficiency and reduce costs. If competitors leverage AI to streamline their operations or reduce the costs associated with R&D, they might be able to offer products at lower prices or with higher margins. Gilead may face pressure to lower its own prices or invest in new AI technologies to maintain a competitive position, which can affect profit margins.
Overall, while AI presents various risks to Gilead Sciences, the company’s response, including its investment in AI technologies and its ability to innovate, will play a crucial role in determining the actual impact of these threats on its products, services, and competitive positioning.
Sensitivity to interest rates
Gilead Sciences, like many companies, is affected by changes in interest rates in a few key ways regarding its earnings, cash flow, and valuation.
1. Cost of Borrowing: If interest rates rise, the cost of borrowing increases. Gilead, which may rely on debt for financing operations, acquisitions, or research and development, could face higher interest expenses. This could reduce net income and cash flow from operations.
2. Valuation Impact: Higher interest rates typically result in a higher discount rate used in discounted cash flow models. This can lead to a lower present value of expected future cash flows, thereby impacting the company’s market valuation negatively. Investors may also demand higher rates of return, further compressing the stock price.
3. Investment Decisions: Rising interest rates can lead to a tighter capital environment, potentially impacting Gilead’s ability to invest in new projects or research initiatives. Reduced investment could slow down growth and innovation, affecting long-term earnings potential.
4. Market Sentiment: The biotechnology and pharmaceutical sectors can be sensitive to macroeconomic conditions, including interest rates. If investors anticipate higher rates leading to economic slowdown, it may result in lower stock prices for companies like Gilead, as market sentiment shifts.
5. Cash Flow Management: Changes in interest rates can impact operating cash flows indirectly through shifts in consumer and business spending. If higher rates lead to economic contraction, this may affect sales of Gilead’s products, thus impacting cash flows.
In summary, Gilead Sciences’ earnings, cash flow, and valuation are moderately sensitive to changes in interest rates through borrowing costs, valuation methods, investment capacities, market sentiment, and overall economic conditions.
Resilience to the future changes
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

πŸ”“ Unlock our free guide: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

T25lIHJlYW xpc3RpYyBz Y2VuYXJpby B0aGF0IGNv dWxkIHBlcm 1hbmVudGx5 IGltcGFpci BHaWxlYWQg U2NpZW5jZX PigJkgZWNv bm9taWNzIG 92ZXIgdGhl IG5leHQgM+ KAkzUgeWVh cnMgaXMgdG hlIGxvc3Mg b2YgZXhjbH VzaXZpdHkg YW5kIGNvbX BldGl0aXZl IG1hcmtldC BwcmVzc3Vy ZXMgaW4gaX RzIGNvcmUg dGhlcmFwZX V0aWMgYXJl YXMsIHBhcn RpY3VsYXJs eSBpbiB0aG UgSElWIGFu ZCBoZXBhdG l0aXMgQyBz ZWdtZW50cy 4gPGJyPkFz IHBhdGVudC Bwcm90ZWN0 aW9ucyBvbi BrZXkgZHJ1 Z3MgbGlrZS BCaWt0YXJ2 eSAoZm9yIE hJVikgYW5k IEhhcnZvbm kgb3IgRXBj bHVzYSAoZm 9yIGhlcGF0 aXRpcyBDKS BleHBpcmUs IEdpbGVhZC BtYXkgZmFj ZSBzaWduaW ZpY2FudCBj b21wZXRpdG lvbiBmcm9t IGdlbmVyaW MgbWFudWZh Y3R1cmVycy BhbmQgYmlv c2ltaWxhcn MuIFRoaXMg ZXJvc2lvbi BvZiBtYXJr ZXQgZXhjbH VzaXZpdHkg Y2FuIGxlYW QgdG8gaW50 ZW5zZSBwcm ljZSBjb21w ZXRpdGlvbi wgc2lnbmlm aWNhbnRseS BpbXBhY3Rp bmcgdGhlIG NvbXBhbnni gJlzIHJldm VudWUgc3Ry ZWFtcy48Yn I+SW4gdGhp cyBzY2VuYX JpbywgR2ls ZWFk4oCZcy BtYXJnaW5z IHdvdWxkIG xpa2VseSBk ZWNyZWFzZS BzdWJzdGFu dGlhbGx5Li BXaXRoIHRo ZSBpbnRyb2 R1Y3Rpb24g b2YgbG93ZX ItY29zdCBh bHRlcm5hdG l2ZXMsIHRo ZSBjb21wYW 55IHdvdWxk IGVpdGhlci BoYXZlIHRv IGxvd2VyIG l0cyBwcmlj ZXMgdG8gcm VtYWluIGNv bXBldGl0aX ZlIG9yIGxv c2UgbWFya2 V0IHNoYXJl LCBsZWFkaW 5nIHRvIHJl ZHVjZWQgZ3 Jvc3MgbWFy Z2lucy4gSW YgZ3Jvc3Mg bWFyZ2lucy BmYWxsIGZy b20gdGhlaX IgY3VycmVu dCBsZXZlbH MgKG9mdGVu IGluIHRoZS ByYW5nZSBv ZiA4MCUgZm 9yIGNlcnRh aW4gcHJvZH VjdHMpIHRv LCBzYXksIG Fyb3VuZCA1 MC02MCUsIG 5ldCBtYXJn aW5zIHdvdW xkIGFsc28g YmUgYWR2ZX JzZWx5IGFm ZmVjdGVkLC BpbXBhY3Rp bmcgcHJvZm l0IGxldmVs cy48YnI+Q2 FzaCBmbG93 IHdvdWxkIG JlIGEgc2ln bmlmaWNhbn QgY29uY2Vy biB1bmRlci B0aGlzIHNj ZW5hcmlvLi BBcyByZXZl bnVlcyBkZW NsaW5lIGR1 ZSB0byBjb2 1wZXRpdGl2 ZSBwcmVzc3 VyZXMgYW5k IHByaWNpbm cgc3RyYXRl Z2llcywgZn JlZSBjYXNo IGZsb3cgY2 91bGQgZGlt aW5pc2ggY2 9uc2lkZXJh Ymx5LiBJZi BHaWxlYWQg dHlwaWNhbG x5IGdlbmVy YXRlcyBiaW xsaW9ucyBp biBmcmVlIG Nhc2ggZmxv dywgYSAzMC 01MCUgcmVk dWN0aW9uIG R1ZSB0byBs b3dlciByZX ZlbnVlcyBh bmQgbWFyZ2 lucyBjb3Vs ZCBsZWFkIH RvIGNoYWxs ZW5nZXMgaW 4gZnVuZGlu ZyByZXNlYX JjaCBhbmQg ZGV2ZWxvcG 1lbnQsIGRp dmlkZW5kcy wgb3Igc2hh cmUgYnV5Ym Fja3MuIFRo ZSBjb21wYW 55IG1pZ2h0 IGFsc28gaG F2ZSB0byBy ZWNvbnNpZG VyIGl0cyBp bnZlc3RtZW 50IHN0cmF0 ZWdpZXMgb3 IgZXhwbG9y ZSBjb3N0LW N1dHRpbmcg bWVhc3VyZX MuPGJyPk9u IHRoZSBiYW xhbmNlIHNo ZWV0LCBHaW xlYWQgY291 bGQgc2VlIG luY3JlYXNl ZCBwcmVzc3 VyZSBpZiBy ZXZlbnVlcy BmYWxsIHNp Z25pZmljYW 50bHkuIFdp dGggZGVjbG luaW5nIGNh c2ggZmxvdy wgdGhlIGNv bXBhbnnigJ lzIGFiaWxp dHkgdG8gbW FpbnRhaW4g aXRzIGNhc2 ggcmVzZXJ2 ZXMgbWF5IG JlIGhhbXBl cmVkLCBsZW FkaW5nIHRv IGEgZGVjcm Vhc2UgaW4g aXRzIGxpcX VpZGl0eSBw b3NpdGlvbi 4gSWYgR2ls ZWFkIGhhcy BleGlzdGlu ZyBkZWJ0IC h3aGljaCBp dCBkb2VzKS wgdGhlcmUg Y291bGQgYm UgcmlzaW5n IGNvbmNlcm 5zIGFib3V0 IGRlYnQgc2 VydmljZSBj b3ZlcmFnZS ByYXRpb3Mu IFRoZSBjb2 1wYW554oCZ cyBsZXZlcm FnZSBjb3Vs ZCBpbmNyZW FzZSBpZiBp dCB0b29rIG 9uIGFkZGl0 aW9uYWwgZG VidCB0byBz dXBwb3J0IG 9wZXJhdGlv bnMgb3IgaW 52ZXN0IGlu IG5ldyBSJm FtcDtELCB0 cmFuc2xhdG luZyB0byBh IGxlc3MgZm F2b3JhYmxl IGZpbmFuY2 lhbCBwb3Np dGlvbi48Yn I+SW4gc3Vt bWFyeSwgaW YgR2lsZWFk IFNjaWVuY2 VzIHdlcmUg dG8gZmFjZS BzaWduaWZp Y2FudCBwYX RlbnQgZXhw aXJhdGlvbn MgYW5kIGlu Y3JlYXNlZC BtYXJrZXQg Y29tcGV0aX Rpb24sIHRo ZSByZXN1bH RpbmcgcHJl c3N1cmUgb2 4gaXRzIHJl dmVudWUgc3 RyZWFtcywg bWFyZ2lucy wgYW5kIGNh c2ggZmxvdy Bjb3VsZCBs ZWFkIHRvIG Egd2Vha2Vu ZWQgYmFsYW 5jZSBzaGVl dCwgaW1wYW N0aW5nIGl0 cyBsb25nLX Rlcm0gdmlh YmlsaXR5IG FuZCBncm93 dGggcHJvc3 BlY3RzLjxi cj4=
Interesting facts about the company
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

πŸ“– Get insights from "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" now!

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvQz J6NWNNdGdW ek9UZkxzcG hRWEoud2Vi cCIgYWx0PS JHaWxlYWQg U2NpZW5jZX MiIHRpdGxl PSJHaWxlYW QgU2NpZW5j ZXMiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 NTAgd2lkdG g9NTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2ls ZWFkIFNjaW VuY2VzPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +SoSBMZWFy biBzbWFydG VyIHN0b2Nr IHBpY2tzIH dpdGggPGk+ IlRoZSBDaG Vja2xpc3Qg VmFsdWUgSW 52ZXN0b3Ig 4oCUIEEgU2 1hcnRlciBX YXkgdG8gUG ljayBTdG9j a3MiPC9pPg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8L3A+Cg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8IS0tCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxkaXYgc3 R5bGU9J21h cmdpbi10b3 A6IDEycHg7 IGZvbnQtc2 l6ZTogMTNw eDsgY29sb3 I6ICM0NDQ7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IFNpZ24gdX Agbm93IGFu ZCBnZXQgb3 VyIGZyZWUg ZUJvb2sgCi AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICA8Yj 5UaGUgQ2hl Y2tsaXN0IF ZhbHVlIElu dmVzdG9yIO KAlCBBIFNt YXJ0ZXIgV2 F5IHRvIFBp Y2sgU3RvY2 tzPC9iPgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L2Rpdj4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgLS0+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID whLS0KICAg ICAgICAgIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nbWFyZ2 luLXRvcDog MTZweDsgZm 9udC1zaXpl OiAxNHB4Oy Bjb2xvcjog IzQ0NDsgZm 9udC1mYW1p bHk6IC1hcH BsZS1zeXN0 ZW0sIEJsaW 5rTWFjU3lz dGVtRm9udC wgU2Vnb2Ug VUksIFJvYm 90bywgSGVs dmV0aWNhIE 5ldWUsIHNh bnMtc2VyaW Y7IGxpbmUt aGVpZ2h0Oi AxLjY7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIEhh dmUgeW91IG hlYXJkIGFi b3V0IG91ci BzaG9ydCA8 c3Ryb25nIH N0eWxlPSdm b250LXdlaW dodDogNjAw Oyc+RGFpbH kgVmlkZW8g TmV3c2xldH Rlcjwvc3Ry b25nPj8KIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIDxhIG hyZWY9J2h0 dHBzOi8vd3 d3Lmluc2ln aHRmdWx2YW x1ZS5jb20v bmV3c2xldH Rlci5waHAn IHRhcmdldD 0nX2JsYW5r JyBzdHlsZT 0nY29sb3I6 ICMwMDdCRk Y7IHRleHQt ZGVjb3JhdG lvbjogbm9u ZTsgZm9udC 13ZWlnaHQ6 IDUwMDsgbW FyZ2luLWxl ZnQ6IDZweD snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIEZp bmQgb3V0IG 1vcmUKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9kaXY+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgIC0tPgog ICAgICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC AgICAgPC9k aXY+CiAgIC AgICAgICAg IDwvZGl2Pg ogICAgICAg ICAgICAKIC AgICAgICAK ICAgICAgIC A8c3BhbiBj bGFzcz0nYm x1cnJlZC10 ZXh0Jz4KIC AgICAgICAg ICAgUjJsc1 pXRmtJRiBO amFXVnVZMl Z6IExDQkpi bU11SUcgbH pJR0VnWW1s diBjR2hoY2 0xaFkyIFYx ZEdsallXd2 cgWTI5dGNH RnVlUyBCaV lYTmxaQ0Jw IGJpQkdiM0 4wWlggSWdR MmwwZVN3Zy BRMkZzYVda dmNtIDVwWV N3Z2EyNXYg ZDI0Z1ptOX lJRyBsMGN5 Qm1iMk4xIG N5QnZiaUJo Ym4gUnBkbW x5WVd3ZyBa SEoxWjNNc0 lIIEJoY25S cFkzVnMgWV hKc2VTQjBh RyA5elpTQj FjMlZrIElI UnZJSFJ5Wl cgRjBJRWhK Vml3ZyBhR1 Z3WVhScGRH IGx6SUVJc0 lHaGwgY0dG MGFYUnBjeS BCRExDQmhi bVFnIGFXNW 1iSFZsYm4g cGhMaUJJWl hKbCBJR0Z5 WlNCemIyID FsSUdsdWRH VnkgWlhOMG FXNW5JRyBa aFkzUnpJR0 ZpIGIzVjBJ SFJvWlMgQm piMjF3WVc1 NSBPanhpY2 o0eExpIEE4 YzNSeWIyNW 4gUGtadmRX NWthVyA1bl BDOXpkSEp2 IGJtYytPaU JIYVcgeGxZ V1FnVTJOcC BaVzVqWlhN Z2QyIEZ6SU dadmRXNWsg WldRZ2FXNG dNVCBrNE55 QmllU0JFIG NpNGdUV2xq YUcgRmxiQ0 JNTGlCUyBh Vzl5WkdGdU xpIEJVYUdV Z1kyOXQgY0 dGdWVlS0Ft WCBNZ2JtRn RaU3dnIFIy bHNaV0ZrTE MgQnBjeUJr WlhKcCBkbV ZrSUdaeWIy IDBnWVNCaW FXSnMgYVdO aGJDQndiRy BGalpTQnJi bTkzIGJpQm 1iM0lnYUcg VmhiR2x1Wn k0OCBZbkkr TWk0Z1BIIE 4wY205dVp6 NUkgU1ZZZ1 RXVmthVyBO aGRHbHZibk 04IEwzTjBj bTl1WnogND ZJRWRwYkdW aCBaQ0JwY3 lCaElHIHhs WVdSbGNpQn AgYmlCa1pY WmxiRyA5d2 FXNW5JR0Z1 IGRHbHlaWF J5YjMgWnBj bUZzSUhSby BaWEpoY0ds bGN5IEJtYj NJZ1NFbFcg TGlCVWFHVW dZMiA5dGNH RnVlZUtBIG 1YTWdaSEox WjMgTXNJSE 4xWTJnZyBZ WE1nVkhKMW RtIEZrWVNC aGJtUWcgUW 1scmRHRnlk biBrc0lHaG hkbVVnIGNH eGhlV1ZrSU cgRWdjMmxu Ym1sbSBhV0 5oYm5RZ2Nt IDlzWlNCcG JpQnAgYlhC eWIzWnBibS BjZ2RHaGxJ R3hwIGRtVn pJRzltSUgg QmxiM0JzWl NCcyBhWFpw Ym1jZ2QyIG wwYUNCSVNW WXUgUEdKeV BqTXVJRCB4 emRISnZibW MrIFNHVndZ WFJwZEcgbH pJRU1nVkhK bCBZWFJ0Wl c1MFBDIDl6 ZEhKdmJtYy sgT2lCSGFX eGxZVyBRZ1 pHVjJaV3h2 IGNHVmtJRk 52ZG0gRnNa R2tnWVc1ay BJRWhoY25a dmJtIGtzSU dkeWIzVnUg WkdKeVpXRn JhVyA1bklI UnlaV0YwIG JXVnVkSE1n Wm0gOXlJR2 hsY0dGMCBh WFJwY3lCRE xpIEJVYUdW elpTQmsgY2 5WbmN5Qm9Z WCBabElISm xkbTlzIGRY UnBiMjVwZW 0gVmtJSFJv WlNCMCBjbV ZoZEcxbGJu IFFnYkdGdV pITmogWVhC bExDQnZabS BabGNtbHVa eUJvIGFXZG 9JR04xY20g VWdjbUYwWl hNZyBZVzVr SUhKbGJHIE YwYVhabGJI a2cgYzJodm NuUWdkSCBK bFlYUnRaVz UwIElHUjFj bUYwYVcgOX VjeTQ4WW5J KyBOQzRnUE hOMGNtIDl1 Wno1RFQxWk ogUkMweE9T QlNaWCBOd2 IyNXpaVHd2 IGMzUnliMj VuUGogb2dT VzRnTWpBeS BNQ3dnUjJs c1pXIEZrSU hKbGNIVnkg Y0c5elpXUW dhWCBSeklH RnVkR2wyIG FYSmhiQ0Jr Y24gVm5JSE psYldSbCBj MmwyYVhJc0 lHIDl5YVdk cGJtRnMgYk hrZ1pHVjJa VyB4dmNHVm tJR1p2IGNp QkZZbTlzWV Mgd2dkRzhn ZEhKbCBZWF FnUTA5V1NV IFF0TVRrdU lGSmwgYldS bGMybDJhWC BJZ2NtVmpa V2wyIFpXUW daVzFsY20g ZGxibU41SU hWeiBaU0Jo ZFhSb2IzIE pwZW1GMGFX OXUgSUdaeW IyMGdkRyBo bElFWkVRU0 JoIGN5QnZi bVVnYjIgWW dkR2hsSUda cCBjbk4wSU dGdWRHIGwy YVhKaGJDQj AgY21WaGRH MWxibiBSek lHWnZjaUJE IFQxWkpSQz B4T1MgNDhZ bkkrTlM0Zy BQSE4wY205 dVp6IDVTWl hObFlYSmog YUNCaGJtUW dSRyBWMlpX eHZjRzFsIG JuUThMM04w Y20gOXVaej Q2SUVkcCBi R1ZoWkNCcG JuIFpsYzNS eklHaGwgWV hacGJIa2dh VyA0Z2NtVn paV0Z5IFky Z2dZVzVrSU cgUmxkbVZz YjNCdCBaVz UwTENCdlpu IFJsYmlCem NHVnUgWkds dVp5QmhJSC BOcFoyNXBa bWxqIFlXNT BJSEJ2Y24g UnBiMjRnYj JZZyBhWFJ6 SUhKbGRtIF Z1ZFdWeklI UnYgSUdScG MyTnZkbSBW eUlHRnVaQ0 JrIFpYWmxi Rzl3SUcgNW xkeUIwYUdW eSBZWEJsZF hScFkzIE1n WVdOeWIzTn ogSUhaaGNt bHZkWCBNZ1 pHbHpaV0Z6 IFpTQmhjbV ZoY3kgd2dh VzVqYkhWay BhVzVuSUc5 dVkyIDlzYj JkNUlHRnUg WkNCcGJtWn NZVyAxdFlY UnZjbmtnIF pHbHpaV0Z6 WlggTXVQR0 p5UGpZdSBJ RHh6ZEhKdm JtIGMrUVdO eGRXbHogYV hScGIyNXpQ QyA5emRISn ZibWMrIE9p QlVhR1VnWT IgOXRjR0Z1 ZVNCbyBZWE 1nWlhod1lX IDVrWldRZ2 FYUnogSUhC dmNuUm1iMi B4cGJ5QjBh SEp2IGRXZG 9JSE4wY20g RjBaV2RwWX lCaCBZM0Yx YVhOcGRHIG x2Ym5Nc0lH bHUgWTJ4MV pHbHVaeSBC aWRYbHBibW NnIFMybDBa U0JRYUcgRn liV0VzSUhk byBhV05vSU dGc2JHIDkz WldRZ1IybH MgWldGa0lI UnZJRyBWdW RHVnlJSFJv IFpTQm1hV1 ZzWkMgQnZa aUJqWld4cy BJSFJvWlhK aGNIIGtnWm 05eUlHTmgg Ym1ObGNpQj BjbSBWaGRH MWxiblF1IF BHSnlQamN1 SUQgeHpkSE p2Ym1jKyBS Mnh2WW1Gc0 lGIEpsWVdO b1BDOXogZE hKdmJtYytP aSBCSGFXeG xZV1FnIGIz QmxjbUYwWl ggTWdhVzRn YjNabCBjaU F6TlNCamIz IFZ1ZEhKcF pYTXMgSUhk cGRHZ2dZUy BCemFXZHVh V1pwIFkyRn VkQ0J3Y20g VnpaVzVqWl NCcCBiaUJG ZFhKdmNHIF VnWVc1a0lF RnogYVdFdU lGUm9aUyBC amIyMXdZVz U1IElHbHpJ R052YlcgMX BkSFJsWkNC MCBieUJ0WV d0cGJtIGNn YVhSeklHMW wgWkdsallY UnBiMiA1ek lHRmpZMlZ6 IGMybGliR1 VnYVcgNGdi RzkzTFNCaC BibVFnYlds a1pHIHhsTF dsdVkyOXQg WlNCamIzVn VkSCBKcFpY TWdkR2h5IG IzVm5hQ0Iy WVggSnBiM1 Z6SUhCeSBh V05wYm1jZ2 MzIFJ5WVhS bFoybGwgY3 lCaGJtUWdj RyBGeWRHNW xjbk5vIGFY QnpManhpY2 ogNDRMaUE4 YzNSeSBiMj VuUGtOdmNu IEJ2Y21GMF pTQlQgYjJO cFlXd2dVbS BWemNHOXVj MmxpIGFXeH BkSGs4TDMg TjBjbTl1Wn o0NiBJRWRw YkdWaFpDIE JwY3lCcGJu WnYgYkhabF pDQnBiaSBC dWRXMWxjbT kxIGN5QnBi bWwwYVcgRj BhWFpsY3lC aCBhVzFsWk NCaGRDIEJw YlhCeWIzWn AgYm1jZ1oy eHZZbSBGc0 lHaGxZV3gw IGFDd2djM1 ZqYUMgQmhj eUJ6ZFhCdy BiM0owYVc1 bklIIEpsYz JWaGNtTm8g SUc5dUlFaE pWaSA5QlNV UlRJSEJ5IF pYWmxiblJw YjIgNGdZVz VrSUhSeSBa V0YwYldWdW RDIEJwYmlC MWJtUmwgY2 kxeVpYTnZk WCBKalpXUW dZMjkxIGJu UnlhV1Z6TG ogeGljajQ1 TGlBOCBjM1 J5YjI1blBr IEZ1Ym5WaG JDQlMgWlha bGJuVmxQQy A5emRISnZi bWMrIE9pQk hhV3hsWVcg UWdhWE1nYj I1bCBJRzlt SUhSb1pTIE JzWVhKblpY TjAgSUdKcG IzUmxZMiBo dWIyeHZaM2 tnIFkyOXRj R0Z1YVcgVn pJR0o1SUhK bCBkbVZ1ZF dVc0lHIE52 Ym5OcGMzUm wgYm5Sc2VT QnlaWCBCdm NuUnBibWNn IFltbHNiR2 x2Ym4gTWdh VzRnY0hKdi BabWwwY3l3 Z1pIIEpwZG 1WdUlHeGgg Y21kbGJIa2 dZbiBrZ2FY UnpJR2x1IG JtOTJZWFJw ZG0gVWdkR2 hsY21GdyBh V1Z6TGp4aW NqIDR4TUM0 Z1BITjAgY2 05dVp6NVhi MyBKcmNHeG hZMlVnIFEz VnNkSFZ5Wl Qgd3ZjM1J5 YjI1biBQam 9nVkdobElH IE52YlhCaG Jua2cgWlcx d2FHRnphWC BwbGN5QmhJ R052IGJHeG hZbTl5WVgg UnBkbVVnWV c1ayBJR2x1 WTJ4MWMyIG wyWlNCM2Iz SnIgY0d4aF kyVWdZMyBW c2RIVnlaU0 JoIGJtUWdh R0Z6SUcgSm xaVzRnY21W aiBiMmR1YV hwbFpDIEJt YjNJZ2FYUn ogSUdWdGNH eHZlVyBWbE xXWnlhV1Z1 IFpHeDVJSE J2YkcgbGph V1Z6SUdGdS BaQ0J3Y21G amRHIGxqWl hNdVBHSnkg UGxSb1pYTm xJRyBaaFkz UnpJR2hwIF oyaHNhV2Rv ZEMgQkhhV3 hsWVdRZyBV Mk5wWlc1al pYIFBpZ0pr Z2MybG4gYm 1sbWFXTmhi biBRZ1kyOX VkSEpwIFlu VjBhVzl1Y3 kgQjBieUJ0 WldScCBZMm x1WlN3Z2NH IEZ5ZEdsam RXeGggY214 NUlHbHVJSC BSb1pTQm1h V1ZzIFpITW diMllnYVcg NW1aV04wYV c5MSBjeUJr YVhObFlYIE 5sY3lCaGJt UWcgYjI1am IyeHZaMyBr dVBHSnlQZz 09CiAgICAg ICAgPC9zcG FuPgogICAg ICAgIAogIC AgICAgIA==
See Company Q&A
Gilead Sciences

πŸ“Š Get full analytics about Gilead Sciences

Sign up for free or log in

πŸ”“ Unlock our free guide: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

© 2024 - 2026 InsightfulValue.com. All rights reserved. Newsletter
Legal